Literature DB >> 12084344

Quality of life following prostate cancer treatments.

D F Penson1.   

Abstract

Quality of life is of major concern to patients when choosing a treatment for prostate cancer. Health-related quality of life (HRQOL) is a patient-centered variable from the field of health services research that can be assessed in a valid and reliable manner. Using standardized questionnaires specifically designed to measure HRQOL in men with prostate cancer, we can now study the effect of various treatments on patients' quality of life. Treatments for metastatic prostate cancer can have significant effects in all areas of patients' quality of life. Patients with localized disease undergoing radical prostatectomy (RP) tend to have more sexual and urinary dysfunction than do men undergoing external beam radiation therapy (EBRT), although both groups have worse quality of life in these areas than age-matched controls. Men undergoing EBRT have worse bowel function than age-matched controls or men undergoing RP. Recent studies of men undergoing interstitial brachytherapy indicate that these patients have less urinary leakage than those who undergo RP, but experience considerably more irritative voiding symptoms, which can profoundly affect quality of life. Patients need to be informed of the possible impact of therapy on quality of life when choosing treatment.

Entities:  

Mesh:

Year:  2000        PMID: 12084344     DOI: 10.1007/s11934-000-0038-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  49 in total

1.  National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer.

Authors:  G P Murphy; C Mettlin; H Menck; D P Winchester; A M Davidson
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

2.  Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy.

Authors:  C L Shrader-Bogen; J L Kjellberg; C P McPherson; C L Murray
Journal:  Cancer       Date:  1997-05-15       Impact factor: 6.860

3.  A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy.

Authors:  H W Herr; A B Kornblith; U Ofman
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

4.  Dimensions of quality of life expressed by men treated for metastatic prostate cancer.

Authors:  J A Clark; N Wray; B Brody; C Ashton; B Giesler; H Watkins
Journal:  Soc Sci Med       Date:  1997-10       Impact factor: 4.634

5.  Quality of life issues relating to endocrine treatment options.

Authors:  P Iversen
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

6.  Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer.

Authors:  K A McCammon; P Kolm; B Main; P F Schellhammer
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

Review 7.  Current results and patient selection for nerve-sparing radical retropubic prostatectomy.

Authors:  M S Steiner
Journal:  Semin Urol Oncol       Date:  1995-08

8.  Quality of life: radical prostatectomy versus radiation therapy for prostate cancer.

Authors:  A J Lim; A H Brandon; J Fiedler; A L Brickman; C I Boyer; W A Raub; M S Soloway
Journal:  J Urol       Date:  1995-10       Impact factor: 7.450

9.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

Authors:  M S Litwin; R D Hays; A Fink; P A Ganz; B Leake; R H Brook
Journal:  Med Care       Date:  1998-07       Impact factor: 2.983

10.  Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey.

Authors:  F J Fowler; M J Barry; G Lu-Yao; J Wasson; A Roman; J Wennberg
Journal:  Urology       Date:  1995-06       Impact factor: 2.649

View more
  2 in total

Review 1.  Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Authors:  Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

Review 2.  The role of estradiol in male reproductive function.

Authors:  Michael Schulster; Aaron M Bernie; Ranjith Ramasamy
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.